Respiratory Disease Vaccine Market Report 2026

Respiratory Disease Vaccine Market Overview

• Respiratory Disease Vaccine market size has reached to $70.03 billion in 2025 • Expected to grow to $81 billion in 2030 at a compound annual growth rate (CAGR) of 3.2% • Growth Driver: The Rising Incidence Of Tuberculosis Fueling Market Growth Due To Increased Infection Burden And Escalating Public Health Risks • Market Trend: Major Players Strive For An Improved Solution Enhancing Efficacy And Prevention • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

What Is Covered Under Respiratory Disease Vaccine Market?

Respiratory diseases refer to a wide range of conditions that affect the airways and lungs, leading to respiratory symptoms and impaired breathing. Respiratory disease vaccine refers to a type of vaccine that is an immunization designed to protect individuals from respiratory infections caused by viruses or bacteria that primarily affect the respiratory system, which includes the lungs and airways. These vaccines work by stimulating the immune system to produce antibodies that can recognize and fight the specific pathogen that causes the disease. The main types of respiratory disease vaccines are viral vaccines, bacterial vaccines and combination vaccines. A viral vaccine is a preparation containing weakened or inactivated viruses that stimulate immune responses and are used to prevent respiratory diseases by training the immune system to recognize and defend against specific viruses, reducing infection spread and severity. They are used in treating infections such as COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia and others in infants, adolescents and adult-aged individuals in clinics, hospitals and others.

What Is The Respiratory Disease Vaccine Market Growth Forecast?

The respiratory disease vaccine market size is expected to see steady growth in the next few years. It will grow to $81 billion in 2030 at a compound annual growth rate (CAGR) of 3.2%. The growth in the forecast period can be attributed to increasing demand for universal vaccines, technological advances in mRNA and viral vector vaccines, expansion of cold-chain infrastructure, growth in public-private partnerships for vaccine distribution, focus on pandemic preparedness and rapid response. Major trends in the forecast period include development of next-generation respiratory vaccines, increased focus on pediatric and geriatric immunization, expansion of immunization programs in emerging markets, rise of combination vaccines for multi-pathogen protection, adoption of rapid vaccine development and distribution platforms.

Global Respiratory Disease Vaccine Market Segmentation

1) By Type: Viral Vaccine, Bacterial Vaccine, Combination Vaccine 2) By Infection: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Other Infections 3) By Age: Infant, Adolescent, Adult 4) By End-User: Clinic, Hospital, Other End-Users Subsegments: 1) By Viral Vaccine: Influenza Vaccine, Respiratory Syncytial Virus (RSV) Vaccine, Coronavirus Vaccine 2) By Bacterial Vaccine: Pneumococcal Vaccine, Haemophilus Influenzae Type B (Hib) Vaccine, Pertussis Vaccine 3) By Combination Vaccine: DTaP With Hib And IPV, Pneumococcal Conjugate Vaccine With Influenza Vaccine

What Is The Driver Of The Respiratory Disease Vaccine Market?

The rising incidence of tuberculosis (TB) is expected to propel the growth of the respiratory disease vaccine market going forward. Tuberculosis is an infectious respiratory illness caused by Mycobacterium tuberculosis, primarily affecting the lungs and representing a significant global health threat. The rise in TB cases is driven by factors such as weakened healthcare systems, delays in diagnosis, and broader transmission patterns, all of which contribute to increased disease burden. Respiratory disease vaccines play a crucial role in mitigating TB-related risks by reducing infection rates, limiting transmission, and supporting global prevention strategies. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the number of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, representing a rise of 1,295 casesTherefore, the rising incidence of tuberculosis is driving the growth of the respiratory disease vaccine industry.

Key Players In The Global Respiratory Disease Vaccine Market

Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc, CureVac N.V., Incepta Vaccine Ltd, Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.

Global Respiratory Disease Vaccine Market Trends and Insights

Major companies operating in the respiratory disease vaccine market are concentrating on creating innovative products to enhance their efficacy and provide improved solutions for preventing and treating respiratory disease infections. For instance, in May 2023, Pfizer Inc., a US-based pharmaceutical company, received Food and Drug Administration (FDA) approval for ABRYSVO (Respiratory Syncytial Virus Vaccine), the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. ABRYSVO is an unadjuvanted vaccine made up of a pair of preF proteins tailored to maximize immunity to RSV A and B varieties and it has been clinically proven to be safe and productive.

What Are Latest Mergers And Acquisitions In The Respiratory Disease Vaccine Market?

In February 2024 AstraZeneca Plc a UK-based biopharmaceutical company, acquired Icosavax, Inc for an undisclosed amount. With this acquisition, AstraZeneca aims to enhance its vaccine development capabilities and expand its pipeline of next-generation immunotherapies. Icosavax Inc is a US-based biotechnology company that specializes in developing virus-like particle (VLP) vaccines targeting infectious diseases.

Regional Insights

Asia-Pacific was the largest region in the respiratory disease vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Respiratory Disease Vaccine Market?

The respiratory diseases vaccine market consists of sales of the rotavirus vaccine, bordetella vaccine and varicella (chickenpox) vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Respiratory Disease Vaccine Market Report 2026?

The respiratory disease vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory disease vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.